ADVERSE PREGNANCY OUTCOMES CATHERINE GIBSON, NARD JANSSEN, WILLEM KIST, ALASTAIR MACLENNAN, BILL HAGUE, ERIC HAAN, PAUL GOLDWATER, KEVIN PRIEST, GUSTAAF DEKKER, Adelaide University, Obstetrics and Gynaecology, Adelaide, South Australia, Australia, VU University Medical Center, Obstetrics and Gynaecology, Amsterdam, Netherlands, Women’s and Children’s Hospital, Adelaide, North Adelaide, South Australia, Australia, Women’s andChildren’sHospital,DepartmentofGeneticMedicine, Adelaide, South Australia, Australia, Women’s and Children’s Hospital, Microbiology and Infectious Diseases, Adelaide, South Australia, Australia, Department of Health, Epidemiology Branch, Adelaide, South Australia, Australia, AdelaideUniversity,MaternalMedicine, Adelaide, SouthAustralia, Australia OBJECTIVE: To investigate the role of fetal inherited thrombophilia in the development of a range of adverse pregnancy outcomes, including pregnancyinduced hypertensive disorders (PIHD), antepartum haemorrhage (APH), intrauterine growth restriction!10th percentile (IUGR) andpretermbirth (PTB). STUDY DESIGN: 717 cases and 609 controls were genotyped for Factor V Leiden (FVL, G1691A), Prothrombin gene mutation (PGM, G20210A), and Methylenetetrahydrofolate reductase (MTHFR) C677T and MTHFR A1298C using genomic DNA extracted from newborn screening cards. RESULTS: For babies born!28 weeks gestation, PGM was associated with an increased risk of IUGR(OR6.40, 1.66-24.71) andAPHwith IUGR(OR6.35, 1.63-24.75). Homozygous PGM also increased the risk of PIHD with IUGR for term-born babies (OR 50.81, 1.75-1476.90). Homozygosity for MTHFR A1298C was associated with an increased risk of IUGR for babies born 28-31 weeks gestation (OR 4.00, 1.04-15.37), and with APH and IUGR for babies born !32 weeks gestation (OR 3.57, 1.09-11.66). MTHFR C677T was associated with a reduced risk of PTB and IUGR (OR 0.52, 0.28-0.96) for babies born 32-36 weeks gestation. Homozygous FVL was associated with an increased risk of PIHD with IUGR for term-born babies (OR 37.15, 1.33-1041.30), but decreased the risk of PTB!32 weeks gestation (OR 0.55, 0.31-0.98). There were no associations with any thrombophilic polymorphism and APH alone. CONCLUSION: These results suggest that some fetal thrombophilic polymorphisms may be related to adverse pregnancy outcomes, in particular IUGR, but this may not be the only association. Further studies matching maternal and fetal genotypes are required to investigate if both are needed for the adverse pregnancy outcome phenotype to be expressed. S14 SMFM Abstracts